Skip to main
ANIX

ANIX Stock Forecast & Price Target

ANIX Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anixa Biosciences is positioned as an early-stage immuno-oncology platform with differentiated approaches in both cancer prevention and treatment, supported by their breast cancer vaccine and ovarian cancer CAR-T therapies. The recent update on their ovarian cancer CAR-T program at a major oncology conference solidifies their progress and enforces ongoing enrollment and investigator engagement. With promising top line revenue numbers for their CAR-T program, Anixa Biosciences shows potential for continued clinical advancement and investor interest.

Bears say

Anixa Biosciences is a biotechnology company with a negative outlook due to its limited financial resources and lack of significant partnerships or collaborations. The company's current reportable segments show a lack of diversification and dependence on its Cancer Vaccines and CAR-T Therapies segments, which have yet to show significant developments or successes in their treatments. This, along with the limited patent licensing activities and lack of revenue-generating products, make it a risky investment option.

ANIX has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anixa Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anixa Biosciences Inc (ANIX) Forecast

Analysts have given ANIX a Strong Buy based on their latest research and market trends.

According to 2 analysts, ANIX has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anixa Biosciences Inc (ANIX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.